Screener

Eligibility screening

Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer

Sponsored by SCRI Development Innovations, LLCStudy detailsClinicalTrials.gov

14 US sites in CO, IL, MD, MN +6

Before we begin

Who are you filling this out for?

Your answer affects how the questions are phrased.